Aquestive shares climb 6% as RTW provides $5M financing lifeline
Biotech beats revenue estimates despite EPS miss, extends Anaphylm marketing deadline amid FDA resubmission timeline
Aquestive Therapeutics shares rose 6% on Wednesday after the biotechnology company secured a $5 million stock purchase commitment from existing investor RTW Investments, providing financial clarity amid a broader $75 million strategic funding agreement tied to its experimental anaphylaxis treatment.
The Warren, New Jersey-based company reported fourth quarter revenue of $13.0 million, slightly beating analyst expectations of $12.9 million. However, the company posted a loss of 15 cents per share, wider than the anticipated 11-cent loss, representing a 36.4% earnings miss.
Despite the earnings shortfall, investors focused on the financing arrangement that will help sustain operations through the regulatory approval process for Anaphylm, a needle-free sublingual film treatment for severe allergic reactions. RTW committed to purchase $5 million of common stock over the next 90 days and received a warrant to purchase 375,000 shares at $4.00 per share, according to the company's announcement. The warrant extends through March 2029.
The financing comes as Aquestive navigates regulatory hurdles after receiving a Complete Response Letter from the U.S. Food and Drug Administration in January. The agency cited deficiencies related to human factors—specifically packaging and administration challenges—rather than concerns about the drug's chemistry, manufacturing, safety, or efficacy. The company has already modified the pouch opening, instructions for use, and labeling in response to the FDA's feedback.
Aquestive said it plans to request a Type A meeting with the FDA within 30 days and expects to resubmit its Anaphylm New Drug Application in the third quarter of 2026, targeting approval in the first quarter of 2027. The company also extended its marketing deadline to June 2027, aligning with the extended regulatory timeline.
For fiscal 2026, Aquestive provided guidance of $46 million to $50 million in revenue, with an expected EBITDA loss between $30 million and $35 million. The company reported a cash position of $121 million, which analysts view as sufficient to fund operations through the resubmission process.
"The $75 million strategic funding agreement with RTW provides significant non-dilutive capital to support the potential launch of Anaphylm," the company stated in its earnings release. The financing is contingent upon FDA approval of the treatment and satisfaction of other conditions.
Beyond the United States, Aquestive is advancing its global regulatory strategy. The company plans to submit marketing authorization applications in Canada and the European Union in the second half of 2026. The European Medicines Agency has provided positive feedback, indicating no further clinical trials are required prior to European submission.
Analysts remain broadly optimistic about the stock's prospects. Nine analysts currently rate Aquestive as a buy or strong buy, with an average price target of $9.22, according to market data. The stock has traded between $2.12 and $7.55 over the past 52 weeks and currently carries a market capitalization of approximately $514 million.
The 6% gain in Wednesday trading reflects investor relief over the secured financing and clearer regulatory path, despite the quarterly earnings miss. With $121 million in cash and the RTW commitment providing additional runway, Aquestive appears positioned to weather the extended timeline for Anaphylm approval while advancing its product pipeline.